R-Pharm International
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, R-Pharm International sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
R-Pharm International: 3 sponsored US clinical trials, none currently recruiting.
R-Pharm International sponsors 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 3 completed. 3 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Rheumatoid Arthritis, with 1 trials.
Upper-quartile sponsor footprint
R-Pharm International sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
3 total, page 1 of 1
Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
NCT03120949
Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease
NCT02760433
Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease
NCT02760407
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 3 |
Therapeutic Areas
How the R-Pharm International archive is shaped
3 indexed studies, none listed as recruiting (0% open); 3 completed (100%).
Phase mix: 3 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Rheumatoid Arthritis (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
R-Pharm International: archived-pipeline peers nationwide
Peers matched on 3 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
R-Pharm International sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 archived trials
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
- 3EO Health · 0% recruiting · 2 trials
Related
What to do with this R-Pharm International page
3 registered trials is a research-attention snapshot, not an endorsement of R-Pharm International or any single study.
- None of R-Pharm International's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Rheumatoid Arthritis is the condition R-Pharm International studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Rheumatoid Arthritis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
R-Pharm International pipeline card: 3 registered trials from official public datasets.Report a data error.